[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


2. Madigan CE, Armenian SH, Malogolowkin MH, Mascarenhas L: Extracranial malignant rhabdoid tumors in childhood: the Childrens Hospital Los Angeles experience. Cancer; 2007 Nov 1;110(9):2061-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracranial malignant rhabdoid tumors in childhood: the Childrens Hospital Los Angeles experience.
  • BACKGROUND: Extracranial malignant rhabdoid tumor (MRT) is a rare, aggressive, pediatric malignancy with a historically poor outcome.
  • Recent efforts to intensify treatment for MRT have resulted in isolated reports of long-term survival.
  • Five patients had renal primary tumors, and 9 patients had extrarenal tumors.
  • Eleven of 14 patients had stage III or IV disease at diagnosis.
  • The time to disease progression was rapid (mean, 3.6 months).
  • There were no recurrences or deaths beyond 10 months after diagnosis.
  • All survivors received multimodal therapy, including both chemotherapy and surgery with or without radiation.
  • In addition, 2 patients received high-dose chemotherapy with hematopoietic stem cell rescue (HSCT) after neoadjuvant chemotherapy and local tumor control.
  • Consolidation with HSCT may benefit selected patients with advanced disease stage.
  • [MeSH-major] Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Hospitals. Humans. Infant. Infant, Newborn. Kaplan-Meier Estimate. Los Angeles. Male. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17828773.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Hosokawa Y, Saiki S, Hanafusa T, Meguro N, Maeda O, Kinouchi T, Kuroda M, Usami M, Kotake T: [A case of adult Wilms' tumor]. Hinyokika Kiyo; 2001 Sep;47(9):641-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult Wilms' tumor].
  • Wilms' tumor is very rarely found in adults and there are no established treatment guidelines for such tumors in adults.
  • Computed tomography scan revealed a large right renal mass with enlarged lymph nodes.
  • Angiography showed a hypovascular tumor.
  • She underwent right nephrectomy and resection of lymph node metastasis with a diagnosis of malignant renal tumor.
  • The disease was classified as stage III according to the National Wilms' Tumor Study classification.
  • The patient received adjuvant chemotherapy consisting of ifosfamide, cisplatin, and etoposide.
  • This protocol was selected because of the published poor results with the standard Wilms' tumor chemotherapeutic agents when used in adults.
  • She remained without tumor recurrence as of six months after surgery.
  • Development of better therapeutic approaches to adult Wilms' tumor is awaited.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692602.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 12
  •  go-up   go-down


Advertisement
4. Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK: Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer; 2007 Nov 15;110(10):2269-75
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
  • METHODS: Twenty-six patients with Stage IV melanoma, measurable or nonmeasurable disease, performance status of 0-2, and adequate renal and hepatic functions were registered.
  • One prior systemic therapy for Stage IV disease was required.
  • RESULTS: After 2 sudden deaths and 1 grade 4 treatment-related pulmonary embolism, this study was temporarily closed.
  • The relationship of these events to the treatment was worrisome but not definitive.
  • Grade 3 treatment-related adverse events occurred in 14 of 26 patients.
  • No treatment responses were seen in the 22 evaluable patients.
  • [MeSH-major] Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17932881.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 4Z8R6ORS6L / Thalidomide; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


5. McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC: The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. Br J Cancer; 2000 Jul;83(1):16-21
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
  • The adjuvant treatment of high-risk malignant melanoma remains problematic.
  • Previously we reported moderate success in the treatment of metastatic disease using tamoxifen, cisplatin, dacarbazine and carmustine.
  • During the first 2 years of follow-up, patients were evaluated every 2 months with a history, physical exam, laboratory work and computed tomography scans of the chest, abdomen and pelvis every 4 months.
  • No effect of gender or number of positive lymph nodes was noted, however, stage of disease prior treatment was a factor.
  • Minimal renal, haematologic and neurologic toxicity occurred.
  • These preliminary results suggest that there is a positive impact of tamoxifen and cisplatin on both the DFS and OS of high-risk malignant melanoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antiemetics / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dexamethasone / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Granisetron / therapeutic use. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Nausea / chemically induced. Nausea / prevention & control. Neoplasm Metastasis. Neoplasm Staging. Ondansetron / therapeutic use. Prognosis. Risk. Survival Analysis. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Treatment Outcome. Vomiting / chemically induced. Vomiting / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1292-5 [2920358.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):736-40 [2016616.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):427-9 [1728371.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):553-6 [1537621.001]
  • [Cites] N Engl J Med. 1992 Aug 20;327(8):516-23 [1635566.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):65-9 [1642409.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6790-6 [1458467.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1571-6 [8453625.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1237-42 [8343260.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1914-8 [8364868.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):1018-22 [8253520.001]
  • [Cites] Am J Clin Oncol. 1994 Feb;17(1):55-9 [8311008.001]
  • [Cites] Lancet. 1994 Apr 9;343(8902):913-4 [7908370.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2119-30 [8156517.001]
  • [Cites] Br J Cancer. 1994 Sep;70(3):449-52 [8080729.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2776-83 [7595738.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):7-17 [8558223.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2083-90 [8683240.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2666-73 [8874325.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1425-9 [9552047.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1884-90 [10561229.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] Cancer Treat Rep. 1987 May;71(5):465-9 [3567970.001]
  • [CommentIn] Br J Cancer. 2000 Jul;83(1):6-7 [10883660.001]
  • (PMID = 10883662.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA52151
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Antiemetics; 094ZI81Y45 / Tamoxifen; 4AF302ESOS / Ondansetron; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; WZG3J2MCOL / Granisetron
  • [Other-IDs] NLM/ PMC2374536
  •  go-up   go-down


6. Yalçin B, Kremer LC, Caron HN, van Dalen EC: High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev; 2010;(5):CD006301
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
  • BACKGROUND: Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence.
  • High-dose chemotherapy and haematopoietic stem cell rescue (i.e. myeloablative therapy) might improve survival.
  • OBJECTIVES: To compare the effectiveness of myeloablative therapy with conventional therapy in children with high-risk neuroblastoma.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing the effectiveness of myeloablative therapy with conventional therapy in high-risk neuroblastoma patients.
  • The meta-analysis of event-free survival showed a significant difference in favour of the myeloablative therapy group (HR 0.78; 95% CI 0.67 to 0.90), as did the meta-analysis of overall survival (HR 0.74; 95% CI 0.57 to 0.98).
  • The meta-analysis of secondary malignant disease and treatment-related death did not show a significant difference between the treatment groups.
  • In one study a significant difference in favour of the conventional therapy group was identified for renal effects, interstitial pneumonitis and veno-occlusive disease, whereas for serious infections and sepsis no significant difference between the treatment groups was identified.
  • AUTHORS' CONCLUSIONS: Based on the currently available evidence, myeloablative therapy seems to be a good treatment option for children with high-risk neuroblastoma.
  • It results in higher survival rates than conventional therapy, although possible higher levels of adverse effects should be kept in mind.
  • A definitive conclusion regarding the effect of myeloablative therapy in different subgroups is not possible.
  • This systematic review only allows a conclusion on the concept of myeloablative therapy; no conclusions can be made regarding the best treatment strategy.
  • Future trials on the use of myeloablative therapy for high-risk neuroblastoma should focus on identifying the most optimal induction and/or myeloablative regimen.
  • These RCTs should be performed in homogeneous study populations (for example, regarding stage of disease and patient age) and have a long-term follow up.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Neuroblastoma / drug therapy
  • [MeSH-minor] Age Factors. Bone Marrow / drug effects. Child. Child, Preschool. Disease-Free Survival. Humans. Infant. Neoplasm Recurrence, Local. Prognosis. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;8:CD006301 [23970444.001]
  • (PMID = 20464740.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


7. Cigolari S, Curcio C, Maiorino A, Sessa R, Cioffi A, Massimo M: Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study. Anticancer Res; 2003 Mar-Apr;23(2C):1803-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.
  • BACKGROUND: The combination of cisplatin and vinorelbine has been shown to be effective in patients with advanced non-small cell lung cancer (NSCLC).
  • Based on these data, we planned to treat patients with stage IIIB NSCLC without malignant pleural effusion and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment.
  • RESULTS: A total of 82 (91.1%) cycles were administered with moderate toxicity: WHO grade (G) 2 and 3 neutropenia occurred in 20 (66.6%) patients, G 3 anaemia occurred in 4 (13.3%), G 3 nausea/vomiting in 20 (66.6%) and G 1-2 renal toxicity in 2 (6.6%).
  • CONCLUSION: The combination of cisplatin and vinorelbine is effective and safe as a neoadjuvant therapy in stage IIIB NSCLC, showing a high response rate (60%) and amenability to surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Patient Compliance. Remission Induction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820462.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


8. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • We observed 3 children of school age with renal carcinoma and one patient with an intrarenal neuroblastoma.
  • Comparing relapse-free survival of stages I, II and III, respectively, there was a reduced survival rate for stage III (p=0.019).
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Radhika S, Bakshi A, Rajwanshi A, Nijhawan R, Das A, Kakkar N, Joshi K, Marwaha RK, Rao KL: Cytopathology of uncommon malignant renal neoplasms in the pediatric age group. Diagn Cytopathol; 2005 May;32(5):281-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of uncommon malignant renal neoplasms in the pediatric age group.
  • Malignant renal neoplasms are common solid tumors in pediatric oncology practice.
  • These include the common Wilms' tumor/nephroblastoma and the uncommon neoplasms such as clear-cell sarcoma of the kidney (CCSK), rhabdoid tumor, renal-cell carcinoma, and others.
  • The aim of this study was to describe in detail the cytopathological features of the histopathologically proven uncommon pediatric renal tumors.
  • Aspirates from Wilms' tumor, which are mesenchyme predominant, show clusters of spindle cells associated with the matrix material.
  • Renal-cell carcinoma of childhood shows similar cytological features as its adult counterpart.
  • Rhabdoid tumor of the kidney is characterized by a monomorphic population of cells with abundant cytoplasm, eccentric nuclei with prominent nucleoli.
  • Intrarenal yolk sac tumor is a rare neoplasm and shows severely pleomorphic cells on aspiration.
  • Further, non-Wilms' renal malignant neoplasms must be distinguished from the common Wilms' tumor so that appropriate chemotherapy protocols may be instituted in cases where the tumor is in an advanced stage of malignancy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Endodermal Sinus Tumor / pathology. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Cell Nucleus / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Staining and Labeling. Wilms Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830360.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Stage AC, Pollock RE, Matin SF: Bilateral metastatic renal synovial sarcoma. Urology; 2005 Feb;65(2):389
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metastatic renal synovial sarcoma.
  • Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis.
  • We describe the first report of bilateral renal metastases from synovial sarcoma in a long-term survivor.
  • Treatment consisted of systemic therapy with bilateral partial nephrectomies.
  • [MeSH-major] Forearm. Kidney Neoplasms / secondary. Sarcoma, Synovial / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Amputation. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Female. Humans. Ifosfamide / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Nephrectomy / methods

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708068.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 3
  •  go-up   go-down


11. Zanagnolo V, Sartori E, Galleri G, Pasinetti B, Bianchi U: Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol; 2004;25(3):315-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical review of 55 cases of malignant ovarian germ cell tumors.
  • PURPOSE OF INVESTIGATION: A retrospective analysis of 55 cases of malignant germ cell tumors in a 20-year period was done to evaluate the impact of conservative surgery and adjuvant treatment on survival and fertility.
  • METHODS: Fifty-five cases of malignant ovarian germ cell tumors (MOGCTs) were studied.
  • RESULTS: Thirty-nine patients (71%) presented with FIGO surgical Stage I disease.
  • Postoperative systemic chemotherapy was administered to 40 women (73%), 27 (68%) had received conservative treatment.
  • One woman developed renal failure after the first cycle of chemotherapy and died a few days thereafter and there was one case of bleomycin-induced death due to pulmonary fibrosis.
  • CONCLUSION: The management of MOGCTs with fertility-sparing surgery is a safe, practicable treatment option.
  • The majority of these patients can retain normal ovarian function and reproductive potential after chemotherapy treatment.
  • [MeSH-major] Germinoma / epidemiology. Germinoma / therapy. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Female. Humans. Infertility, Female / epidemiology. Interviews as Topic. Italy / epidemiology. Medical Records. Middle Aged. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15171308.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Hadley GP, Govender D, Landers G: Malignant solid tumours in neonates: an African perspective. Pediatr Surg Int; 2002 Dec;18(8):653-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant solid tumours in neonates: an African perspective.
  • Malignant tumours in the neonate are distinct pathologically, clinically, and therapeutically from those in older children or adults.
  • Neuroblastoma (NB) was the commonest tumour seen (11), but the soft-tissue sarcomas were the dominant group (14).
  • Chemotherapy, despite appropriate dose reduction, had significant morbidity and mortality.
  • Stage I disease was associated with a good prognosis, whilst stage IV disease was uniformly fatal.
  • Stage IVs disease had only 50% early survival.
  • Patients with renal tumours, whether nephroblastoma or mesoblastic nephroma, did well.
  • [MeSH-minor] Female. Humans. Infant, Newborn. Male. Neoplasm Staging. South Africa / epidemiology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12598957.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Camassei FD, Arancia G, Cianfriglia M, Bosman C, Francalanci P, Ravà L, Jenkner A, Donfrancesco A, Boldrini R: Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Am J Clin Pathol; 2002 Mar;117(3):484-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
  • The development of chemoresistance in a variety of cancers seems related to overexpression of the P-glycoprotein (P-gp) drug pump.
  • Nephroblastoma, the most common malignant renal tumor of childhood, usually is responsive to treatment, and prognosis is favorable in most cases.
  • However, the disease in a subset of patients is refractory to treatment, and the disease follows an aggressive course.
  • To study P-gp expression in this tumor and its correlation with outcome, tumor samples from 93 patients were examined by immunohistochemical analysis.
  • P-gp expression was determined separately in both tumor cells and intratumoral capillary endothelium.
  • The likelihood ratio test, the Kaplan-Meier method, and the log-rank test were used to evaluate its association with clinical course, grade, stage, and administration of preoperative chemotherapy.
  • While no association of P-gp expression in tumor cells with clinical course, stage, and grade could be demonstrated, positivity in endothelial cells correlated significantly with unfavorable outcome, suggesting that chemoresistance depended on an active blood-tumor barrier.
  • Previous chemotherapy induced P-gp overexpression in tumor cells.
  • [MeSH-major] Kidney Neoplasms / chemistry. Kidney Neoplasms / pathology. P-Glycoprotein / analysis. Wilms Tumor / chemistry. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capillaries. Child. Child, Preschool. Combined Modality Therapy. Dactinomycin / therapeutic use. Endothelium, Vascular / chemistry. Female. Humans. Immunohistochemistry. Infant. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Radiotherapy. Remission Induction. Retrospective Studies. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11888090.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / P-Glycoprotein; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; SIOP protocol
  •  go-up   go-down


14. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F: Nephron-sparing surgery for unilateral primary renal tumor in children. J Pediatr Surg; 2001 Feb;36(2):362-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron-sparing surgery for unilateral primary renal tumor in children.
  • PURPOSE: Definition of the role of nephron-sparing surgery (NSS) in the treatment of children with primary unilateral renal tumor (URT).
  • Criteria for selection of patients eligible for NSS were at least 50% of affected kidney preservable and stage I at surgery (frozen section biopsies from regional lymph nodes, perirenal fat, and surrounding renal parenchyma).
  • Preoperative 2-drug chemotherapy was given to all patients more than 6 months of age.
  • Between 1992 and 1995, 3-drug chemotherapy was used after NSS.
  • Thereafter, following NSS, 2-drug chemotherapy was given if no microscopic residual disease was found on final histologic examination.
  • Seven children had standard histology nephroblastoma, 1 highly differentiated epithelial type nephroblastoma, 1 oncocytoma, and 1 cystic nephroma.
  • All children are alive and disease free with good functioning of the affected kidney after NSS, at a mean follow-up of 40.7 months (range, 2 to 100 months).
  • CONCLUSION: NSS should be considered in selected children with URT, especially in patients with increased risk for metachronous tumor or renal disease, and in patients with benign or low-grade malignant URT.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Child. Child, Preschool. Eligibility Determination. Female. Humans. Infant. Infant, Newborn. Life Expectancy. Male. Neoplasm Staging. Postoperative Complications. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11172435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Karthaus M, Metzner D, Maher G, Plahl A, Wert N: Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM). J Clin Oncol; 2004 Jul 15;22(14_suppl):7201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM).
  • : 7201 Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the lining of the lung.
  • Only case reports are available for treatment and outcome of AbM.
  • A total of 49 mesothelioma pts with stage III/IV were observed between 12/02 and 11/03.
  • Pts received pemetrexed based therapy including dexamethasone prophylaxis for skin rash on day -1 to+2 additionally.
  • Study endpoints were response (RR), time to progression (TTP) and safety.
  • RESULTS: Four pts (1 AbM, 1 MPM, 2 MPM+AbM) were excluded due to renal impairment (n=1) or death prior to chemotherapy (n=3).
  • Staging revealed AbM in 11 pts, MPM in 30 pts, while 4 pts had malignant mesothelioma on both sites of the diaphragma.
  • Treatment and response data are given in the table below.
  • CONCLUSIONS: Pemetrexed in combination with DDP is a well tolerable and active regimen for advanced peritoneal malignant mesothelioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Pascual Samaniego M, Calleja Escudero J, Alvarez Gago T, Gonzalo Rodríguez V, Müller Arteaga C, Fernández del Busto E: [Adult Wilms' tumor]. Actas Urol Esp; 2004 Jul-Aug;28(7):544-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult Wilms' tumor].
  • [Transliterated title] Tumor de Wilms del adulto.
  • Wilms' tumor is a malignant embryonic renal neoplasm that is exceptional in adults.
  • There are not clinical data or radiographic investigations that can distinguish it from renal cell carcinoma.
  • It may be cystic and must be consider in the differential diagnosis of cystic lesions of the kidney.
  • The prognosis of Wilms' tumor in adults is worse than in children because of the high recurrence, the lower response rate to chemotherapy regimens and the advanced stage at the time of clinical presentation, like an asymptomatic abdominal mass in 75% of the cases.
  • We report a new case of nephroblastoma in a 29 years old woman presenting like a renal colic, with a cystic configuration by abdominal ultrasound initially, that changed into a solid renal mass later.
  • There is not a definitive treatment protocol currently but some authors suggest a combination chemotherapy with carboplatin and etoposide because it is very effective in recurrent or refractory adult Wilms' tumor.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Adult. Female. Humans. Nephrectomy / methods. Tomography, X-Ray Computed. Treatment Outcome. Urography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15384282.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


17. Suita S, Kinoshita Y, Tajiri T, Hara T, Tsuneyoshi M, Mizote H, Inada H, Takamatsu H, Kawano Y, Inomata Y, Nagasaki A, Ono Y, Handa N, Okamura J, Ishii E, Kawakami K, Committee for pediatric solid malignant tumors in the Kyushu area: Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2006 Sep;41(9):1501-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • BACKGROUND/PURPOSE: Since 1996, the standard treatment of Wilms tumors in Japan has been based on the regimen of the Japanese Wilms Tumor Study.
  • This study aims to assess the clinical characteristics of patients with Wilms tumor with a favorable histology from a retrospective standpoint in the Kyushu area in Japan and, furthermore, to analyze the historical changes of clinical features and outcome from the 1980s to the 1990s.
  • RESULTS: The clinical features (age, sex, initial symptom, location, stage) demonstrated no definite differences between group A and group B.
  • All stage V cases in group B undewent a bilateral tumor biopsy instead of a radical nephrectomy as the initial operation.
  • Of particular note, the outcome of patients with stage I and stage V in group B substantially improved in comparison to that in group A.
  • The present study suggested that in the early-stage cases, an initially complete resection followed by standard postoperative chemotherapy substantially improved the outcome of the patients in group B.
  • In the stage V cases, the performance of renal salvage surgery may have positively contributed to the improvement in the outcome in group B.
  • However, in the advanced stage cases, no definite improvement was noted.
  • In the future, an improved efficacy of the treatments for Wilms tumors based on the standard protocol established by the Japanese Wilms Tumor Study in 1996 is expected in Japan.
  • [MeSH-major] Kidney Neoplasms / mortality. Wilms Tumor / mortality
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Japan. Male. Neoplasm Staging. Nephrectomy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952581.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kalajian AH, Malhotra PS, Callen JP, Parker LP: Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed. Arch Dermatol; 2009 Apr;145(4):451-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed.
  • Although traditionally observed in patients with end-stage renal disease and/or hyperparathyroidism, the development of calciphylaxis in "nontraditional" patients having both normal renal and parathyroid function has been reported.
  • OBSERVATIONS: A 58-year-old woman with endometrial carcinoma developed extensive calciphylaxis despite the presence of normal renal and parathyroid function.
  • The disease resolved with rapid diagnosis, supportive therapy, and medical management.
  • Analysis of this case and the 13 previously reported cases of nontraditional calciphylaxis identified the following patient characteristics that highlight clinical situations potentially predisposing to calciphylaxis: hypoalbuminemia, malignant neoplasm, systemic corticosteroid use, anticoagulation with warfarin sodium or phenprocoumon, chemotherapy, systemic inflammation, hepatic cirrhosis, protein C or S deficiency, obesity, rapid weight loss, and infection.
  • CONCLUSIONS: Calciphylaxis is becoming increasingly common in patients with normal renal and parathyroid function.
  • The observations from this study may assist dermatologists in the rapid diagnosis and prompt initiation of therapy for this devastating disease.
  • [MeSH-major] Calciphylaxis / diagnosis. Skin Diseases, Vascular / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / complications. Female. Humans. Middle Aged. Parathyroid Diseases / complications. Renal Insufficiency / complications. Risk Factors

  • Genetic Alliance. consumer health - Calciphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380668.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Basta-Jovanović G, Radonjic V, Stolic I, Nenadovic M, Brasanac D, Jovanovic D, Radojevic-Skodric S: Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor. Ren Fail; 2005;27(1):13-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
  • The rate of apoptosis varies in malignant tumors, and it can be involved in diminishing tumor size.
  • In human renal diseases, such as the experimental model of acute renal failure, and many tumors, including Wilms' tumor, the expression of antiapoptotic members of Bcl-2 family is increased, while the expression of proapoptotic members is low.
  • AIM: The aim of our study was to investigate Bcl-X(S/L) protein expression in Wilms' tumor, to compare it with the expression in normal renal tissue, as well as to see if there is a correlation between Bcl-X(S/L) expression in Wilms' tumor with tumor stage, histological type, prognostic group, or response to preoperative chemotherapy.
  • MATERIALS AND METHODS: Twenty-eight cases of Wilms' tumor (two cases with metastasis) and two samples of normal kidney tissue were studied using streptavidin-biotin-complex technique.
  • RESULTS: The expression of Bcl-X(S/L) was observed in the majority of cases (60.7%), more often in the blastemal than in the epithelial component of Wilms' tumor: 60.7% and 28.6%, respectively (p=0.02).
  • There was a statistically significant inverse relationship between Bcl-X(S/L) expression and tumor stage (p=0.015).
  • Expression of Bcl-X(S/L) was detected in various histological types of Wilms' tumor, but there was no statistically significant association (p=0.82) except in cases with diffuse anaplasia (p=0.012), which were always negative.
  • No Bcl-X(S/L) immunostaining was observed in two cases of metastasis or in one case of bilateral Wilms' tumor.
  • CONCLUSION: Our results suggest that the expression of Bcl-X(S/L) protein is associated with prognostic group, tumor stage, and presence of anaplasia.
  • [MeSH-major] Kidney / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Wilms Tumor / metabolism
  • [MeSH-minor] Anaplasia. Antineoplastic Agents / therapeutic use. Apoptosis. Child. Child, Preschool. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. bcl-X Protein

  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717629.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein
  •  go-up   go-down


20. Thijssens K, Vaneerdeweg W, Schrijvers D, Eyskens E, Van Oosterom A: Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer. Acta Chir Belg; 2003 Nov-Dec;103(6):599-602
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
  • OBJECTIVE: To assess the results of retroperitoneal lymph node dissection (RPLND) of residual masses in patients with disseminated non-seminomatous germ cell tumour treated with cisplatin-based chemotherapy, both in terms of extension of surgery, morbidity and survival.
  • In patients with non-seminomatous testicular cancer more than stage I, the 'wait and see' strategy changed and patients were treated with chemotherapy.
  • Patients were assessed at the end of chemotherapy and if a residual masses persisted, a RPLND was performed.
  • RESULTS: Sixty patients had a non-seminomatous germ cell tumor of the testis and were analysed.
  • Thirteen patients with stage I disease were treated with orchiectomy only and none of these patients had recurrent disease.
  • Forty-seven patients were treated with cisplatin-based chemotherapy.
  • Fifteen patients underwent RPLND above the level of the renal trunk.
  • In two patients malignant cells or fibrotic tissue were found above the renal trunk and bilateral.
  • In five patients viable tumour cells were found in the region below the renal trunk.
  • Sixteen patients underwent RPLND below the level of the renal trunk, of which nine had a unilateral resection, containing viable tumour in two patients.
  • The survival of the patients treated with a RPLND was 97% and in the whole group of patients with a non-seminomatous testicular cancer 98%.
  • CONCLUSION: RPLND has a place in the treatment of patients with non-seminomatous testicular cancer after chemotherapy in case of residual masses.
  • In a limited number of patients there was a need of resection of adherent organs when a resection above the renal trunk was performed.
  • [MeSH-minor] Adult. Belgium. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743567.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


21. Dieleman FJ, Dekker AW: [Kahler's disease. Multiple myeloma]. Ned Tijdschr Tandheelkd; 2007 May;114(5):228-30
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kahler's disease, multiple myeloma, is a malignant condition of unbridled multiplication of plasma cells in bone marrow.
  • In the final stage of the disease severe renal failure can occur.
  • With the present chemotherapy a good response is seen in 50-70% of patients, but complete response occurs only in a minority of patients.
  • Radiotherapy is often used in addition to chemotherapy.
  • In order to minimize the risk of complications, it is advocated to be in touch with the patients haematologist before starting an invasive oral treatment.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Multiple Myeloma / diagnosis
  • [MeSH-minor] Bone Resorption. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17552301.001).
  • [ISSN] 0028-2200
  • [Journal-full-title] Nederlands tijdschrift voor tandheelkunde
  • [ISO-abbreviation] Ned Tijdschr Tandheelkd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Buchner AM, Sonnenberg A: Medical diagnoses and procedures associated with clostridium difficile colitis. Am J Gastroenterol; 2001 Mar;96(3):766-72
Genetic Alliance. consumer health - Clostridium Difficile.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The Patient Treatment File of the Department of Veterans Affairs contains the computerized records of all inpatients treated in 172 Veterans Affairs hospitals distributed throughout the United States.
  • The computerized medical records of 15,091 cases with C. difficile colitis and 61,931 controls without the diagnosis were extracted from the annual files between 1993 and 1998.
  • The numbers of procedures were 75,479 and 129,612, respectively. C. difficile colitis was significantly associated with HIV infection, candidiasis, malignant neoplasm and chemotherapy, malnutrition, pneumonia, aspiration pneumonitis, intestinal obstruction, diverticulitis, renal failure, urinary tract infection, decubitus, and osteomyelitis.
  • Interventional procedures involving the respiratory tract, bone marrow biopsy, arterial and venous catheterization, urinary catheterization, dialysis, gastrostomy tube, and physical therapy were also frequently associated with the development of C. difficile colitis.
  • CONCLUSIONS: These associations reflect the influence of causal relationships (such as the use of antibiotics and chemotherapy), an increased risk of exposure to C. difficile among immobilized bedridden patients with chronic disease states, or a general system failure in patients with end-stage disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280548.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. García-Campelo R, Quindós M, Vázquez DD, López MR, Carral A, Calvo OF, Soto JM, Grande E, Durana J, Antón-Aparicio LM: Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anticancer Drugs; 2010 Jan;21 Suppl 1:S13-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma.
  • A 75-year-old-man, with a 2-month history of abdominal pain, underwent a standard diagnostic workup that included a CT scan that showed a large right renal mass and subcentimeter nodes in the right and left lung lobes.
  • In December 2003, the patient underwent right nephrectomy with adrenalectomy and a diagnosis of renal cell carcinoma (pT3N0M0 stage) was made.
  • No further treatment was proposed and patient was followed up regularly.
  • In October 2006, the annual gastrointestinal endoscopy showed asymptomatic multilobulated and polypoid masses in the gastric fundus and gastric body that corresponded to metastasis of the renal carcinoma that had been resected three years ago.
  • Surgical treatment was refused and oral treatment with sunitinib (50 mg/day consecutively for 4 weeks followed by 2 weeks off) was initiated.
  • Patient completed one cycle and development of acute toxicity (grade 3 asthenia, anorexia and mucositis) led to treatment interruption.
  • After recovering from acute toxicity, the patient was proposed to reinitiate treatment with dose reduction, but he refused any medical treatment.
  • At the follow-up visit, three months later, the gastrointestinal endoscopy showed four unspecific 2 mm nodules without malignant evidence.
  • PET scan six months after treatment confirmed complete gastric response.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / secondary. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Protein Kinase Inhibitors / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Adrenalectomy. Aged. Humans. Male. Neoplasm Metastasis. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110781.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


24. Wertel I, Barczynski B, Kotarski J: The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. Front Biosci; 2008;13:2177-90
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment.
  • Ovarian cancer is the most lethal gynecological malignancy.
  • At the time of diagnosis most patients present with an advanced stage of the disease and require multidisciplinary systemic treatment, including surgery and adjuvant chemotherapy.
  • Despite good initial response to cytostatics, the vast majority of patients develops a recurrence and will need novel therapeutic strategies, as relapsed ovarian cancer is still incurable.
  • One promising treatment option is the use of dendritic cells (DCs) which might induce effective anti-tumor immunity.
  • The ability of DCs to generate an anti-cancer response has been documented in various kinds of human tumors, including malignant melanoma, renal cell carcinoma, and breast cancer tumors.
  • Although DCs were identified in the micro-environment of ovarian cancer, lack of clearly defined ovarian-specific tumor antigens capable of being recognized by T cells is considered the major prohibiting factor in ovarian cancer vaccine development.
  • There is therefore a strong need to identify and employ attractive candidates for tumor-specific antigens.
  • In this review we will focus on current knowledge of the influence of DC mechanisms of cytotoxic T-cell responses and recent advances in DC identification in ovarian cancer patients, in addition to summarizing the data on DC vaccinations in these patients.
  • [MeSH-minor] Animals. Antigen Presentation. Antigens, Neoplasm / chemistry. CD8-Positive T-Lymphocytes / immunology. Clinical Trials as Topic. Female. Humans. Immune System. Immunotherapy / methods. Ligands. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981701.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Ligands
  • [Number-of-references] 142
  •  go-up   go-down


25. Parmeggiani F, Costagliola C, D'Angelo S, Incorvaia C, Perri P, Sebastiani A: Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy. Oncology; 2004;66(6):502-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy.
  • BACKGROUND/OBJECTIVE: Clear cell renal cell carcinoma (CCRCC) is a malignant neoplasm frequently associated with an increase in circulating immune complexes (CIC).
  • Histopathologic review of his surgically removed organs (kidney and lung), periodical laboratory immunologic tests and ophthalmologic examinations, including fluorescein and indocyanine green angiographies, were performed.
  • RESULTS: The patient underwent total left nephrectomy (May 1997) and total left pneumonectomy (March 2001) for the presence of stage III CCRCC and CCRCC lung metastasis, respectively.
  • CONCLUSIONS: Long-standing tumorous disease, through a pathogenic mechanism triggered by CIC spreading, can be responsible, over time, for a progressive choroidal occlusive microangiopathy (atypical APMPPE pattern), associated with a high risk of poor visual outcome.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Choroidal Neovascularization / etiology. Kidney Neoplasms / pathology. Pigment Epithelium of Eye / pathology
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Nephrectomy. Pneumonectomy. Vision Disorders / etiology


26. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakanishi H, Nakao M, Miki T: Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur J Cancer; 2003 Mar;39(4):541-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
  • DPD is also the principal enzyme involved in the degradation of 5-fluorouracil (5-FU), an anticancer chemotherapeutic agent that is used clinically to treat renal cell carcinoma (RCC).
  • The levels of DPD activity in RCC and normal kidney samples were determined by the 5-FU degradation assay.
  • The activity of DPD was approximately 2-fold higher in normal kidney compared with RCC.
  • DPD activity in Stage I/II RCC was approximately 2-fold higher than that in Stage III/IV RCC.
  • These results suggest that a low DPD activity may be associated with the malignant potential of RCC.
  • In addition, it may be possible to overcome 5-FU resistance by using DPD inhibitors in the treatment protocols of 5-FU-based chemotherapy for RCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Renal Cell / enzymology. Fluorouracil / therapeutic use. Kidney Neoplasms / enzymology. Oxidoreductases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dihydrouracil Dehydrogenase (NADP). Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12751387.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.- / Oxidoreductases; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); U3P01618RT / Fluorouracil
  •  go-up   go-down


27. van den Hoek J, de Krijger R, van de Ven K, Lequin M, van den Heuvel-Eibrink MM: Cystic nephroma, cystic partially differentiated nephroblastoma and cystic Wilms' tumor in children: a spectrum with therapeutic dilemmas. Urol Int; 2009;82(1):65-70
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma, cystic partially differentiated nephroblastoma and cystic Wilms' tumor in children: a spectrum with therapeutic dilemmas.
  • BACKGROUND: Cystic renal tumors are a diagnostic and therapeutic challenge.
  • Cystic nephroma (CN), cystic partially differentiated nephroblastoma (CPDN) and cystic Wilms' tumor (CWT) are a spectrum with CN at the benign end, CWT at the malignant end and CPDN in the intermediate position.
  • CN and stage 1 CPDN are often treated with surgery alone.
  • International Society of Pediatric Oncology (SIOP) protocols for Wilms' tumor (WT) advocate preoperative chemotherapy, which may be unnecessary and potentially harmful in CN and in stage 1 CPDN.
  • There are difficulties in differentiating the three types using imaging techniques.
  • Therefore, controversies exist regarding the optimal treatment.
  • METHODS: We describe 6 children, who each had a postoperative diagnosis of CN, CPDN or CWT, and we retrospectively evaluate the treatment strategies.
  • RESULTS: The three types cannot be differentiated using imaging techniques, although the presence of solid components in the tumor is indicative of WT.
  • CONCLUSIONS: Surgery as first-line therapy should be seriously considered in children who have a cystic renal tumor, but further collaborative studies are needed since the distinction line between CPDN and CWT is not always clear.
  • [MeSH-major] Kidney Diseases, Cystic / surgery. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Cell Differentiation. Chemotherapy, Adjuvant. Child, Preschool. Diagnosis, Differential. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19172100.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Zachariou Z, Sieverts H, Eble MJ, Gfrörer S, Zavitzanakis A: IORT (intraoperative radiotherapy) in neuroblastoma: experience and first results. Eur J Pediatr Surg; 2002 Aug;12(4):251-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperative radiotherapy (IORT) permits the application of a single large radiation dose to a malignant mass at the time of surgery sparing adjacent normal tissue from irradiation.
  • Since 1996 we have used IORT to treat 13 children with neuroblastoma, stage 3 - 4.
  • Ultrasound, CT and MRI were performed and patients were treated with chemotherapy according to the NB90 protocol.
  • Localised radiation of the residual tumour was 8 - 10 Gy.
  • The follow-up time was 6 - 69 months (May 2001).
  • The clinical course of 2 patients was complicated by a renal artery stenosis and a mesenteric artery occlusion.
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Intraoperative Period. Neoplasm Staging. Retrospective Studies. Second-Look Surgery

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12369003.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Djeu JY, Wei S: Clusterin and chemoresistance. Adv Cancer Res; 2009;105:77-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to anticancer agents is one of the primary impediments to effective cancer therapy.
  • Chemoresistance occurs not only to clinically established therapeutic agents but also to novel targeted therapeutics.
  • Both intrinsic and acquired mechanisms have been implicated in drug resistance but it remains controversial which mechanisms are responsible that lead to failure of therapy in cancer patients.
  • Its role has been documented in prostate cancer for paclitaxel/docetaxel resistance as well as in renal, breast, and lung tumor cells.
  • Moreover, it is abnormally upregulated in numerous advanced stage and metastatic cancers spanning prostate, renal, bladder, breast, head and neck, colon, cervical, pancreatic, lung carcinomas, melanoma, and lymphoma.
  • It is noteworthy that only the cytoplasmic/secretory clusterin form (sCLU), and not the nuclear form, is expressed in aggressive late stage tumors, which is in line with its antiapoptotic function.
  • Resistance to targeted death-inducing molecules, tumor necrosis factor, Fas and TRAIL, or histone deacetylase inhibitors can also be mediated by sCLU.
  • Expression of sCLU may be an adaptive response to genotoxic and oxidative stresses but this adaptive response could pose a threat in malignant cells being treated with cytotoxic agents by enhancing their survival potential.
  • The actual mechanisms for sCLU induction are unclear but STAT1 is required for its constitutive upregulation in docetaxel-resistant tumor cells.
  • Thus, sCLU has a key role in preventing apoptosis induced by cytotoxic agents and has the potential to be targeted for cancer therapy.
  • [MeSH-major] Clusterin / physiology. Drug Resistance, Neoplasm. Neoplasms / drug therapy
  • [MeSH-minor] Drug Resistance, Multiple. Humans. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1300-7 [15955107.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):909-15 [16113678.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96 [16145049.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Mar;2(3):150-7 [16264908.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1837-49 [16373699.001]
  • [Cites] Biochem J. 2006 Apr 1;395(1):223-31 [16336210.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):269-80 [16683005.001]
  • [Cites] Urology. 2006 Sep;68(3):609-14 [16979705.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6113-22 [16652143.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):611-22 [17096323.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2278-87 [17148459.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):9-23 [17084534.001]
  • [Cites] Histopathology. 2007 Feb;50(3):331-7 [17257128.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Apr;4(4):236-44 [17392714.001]
  • [Cites] Neoplasia. 2001 Jul-Aug;3(4):360-7 [11571636.001]
  • [Cites] Mol Urol. 2001 Autumn;5(3):105-11 [11690557.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4245-52 [11751526.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):179-88 [11813210.001]
  • [Cites] Cell Stress Chaperones. 2002 Jan;7(1):23-35 [11892985.001]
  • [Cites] Urology. 2002 Sep;60(3):516-20 [12350509.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3276-84 [12374699.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):320-9 [12652308.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4):372-80 [14508108.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38214-9 [12882985.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1834-42 [14996747.001]
  • [Cites] Mol Cancer Ther. 2004 Mar;3(3):223-32 [15026542.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2298-304 [14755245.001]
  • [Cites] Cell Cycle. 2009 Feb 1;8(3):473-81 [19177010.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(10):1846-54 [19342222.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):791-806 [19391138.001]
  • [Cites] Oncogene. 2009 Sep 17;28(37):3307-19 [19597465.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):170-6 [10646870.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2547-54 [10811138.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1655-63 [10815883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5907-12 [10823943.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21055-60 [10770937.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):393-9 [10934144.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G149-56 [11123208.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Urology. 2001 Aug;58(2 Suppl 1):39-49 [11502446.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3126-36 [15126350.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2477-81 [15126879.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Prostate. 2004 Dec 1;61(4):318-23 [15389725.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Aug 31;147(1):196-203 [3632663.001]
  • [Cites] Biochem J. 1989 Jan 1;257(1):293-6 [2920020.001]
  • [Cites] Mol Cell Biol. 1989 Aug;9(8):3473-81 [2477686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8577-81 [1924317.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6940-4 [1458483.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(3):186-8 [8263017.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2431-7 [7757997.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):229-33 [9000560.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26620-6 [9334243.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30777-84 [9804855.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31068-74 [9813006.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1596-605 [17404365.001]
  • [Cites] ChemMedChem. 2007 Jul;2(7):920-42 [17530726.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1772(9):1103-11 [17689225.001]
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):2938-47 [18025278.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2782-7 [17998803.001]
  • [Cites] Kidney Int. 2008 Mar;73(5):567-77 [18075502.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):527-32 [18177691.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):12851-61 [18321852.001]
  • [Cites] J Urol. 2008 Aug;180(2):565-70; discussion 570 [18554663.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):48-59 [19118032.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):403-6 [19147550.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):708-13 [19147778.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6B):2566-85 [19210756.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1707-11 [9815554.001]
  • [Cites] Prostate. 1999 May;39(2):87-93 [10221563.001]
  • [Cites] Eur J Biochem. 1999 Jul;263(2):534-42 [10406964.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):277-83 [15578711.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95 [15663992.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14212-21 [15689620.001]
  • [Cites] J Cell Physiol. 2005 Aug;204(2):463-9 [15685647.001]
  • (PMID = 19879424.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098080
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLU protein, human; 0 / Clusterin
  • [Number-of-references] 78
  • [Other-IDs] NLM/ NIHMS539156; NLM/ PMC3889866
  •  go-up   go-down


30. Yashi M, Nukui A, Kurokawa S, Ochi M, Ishikawa S, Goto K, Kobayashi Y, Muraishi O, Tokue A: Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate; 2003 Sep 1;56(4):305-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
  • BACKGROUND: The neuroendocrine (NE) pathway has been attracting attention as a mechanism for the androgen-independent progression because the neuropeptide provokes tumor growth and inhibits apoptosis under androgen-deprived milieu in prostate cancer cells.
  • On the basis that serum progastrin-releasing peptide (ProGRP) is elevated in patients with advanced disease stage, we examined the prognostic value of the neuropeptide.
  • METHODS: Serum ProGRP status was determined with an enzyme-linked immunosorbent assay (ELISA) in 460 men with benign and malignant prostatic diseases, chronic renal failure, and healthy controls.
  • Seventy patients with metastatic prostate cancer including four patients (5.7%) with NE carcinoma who underwent hormonal therapy were enrolled in the prognostic analyses by Cox proportional hazards model.
  • RESULTS: The serum status steadily shifted toward predominant expression of ProGRP with the progression of prostate cancer into metastatic and androgen-independent stages.
  • Serum ProGRP was the most significant predictor among pre-treatment factors in this model (P = 0.0094).
  • CONCLUSIONS: The neuropeptide precursor ProGRP is a distinct serum marker that is useful to know the NE milieu and provides prognostic information in patients with advanced prostate cancer.
  • Standard therapy for metastatic prostate cancer may make progress when further studies will clarify the causative link between serum ProGRP level and androgen-independent disease progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Hormones / analysis. Neoplasm Metastasis. Neoplasm Staging / methods. Peptide Fragments / analysis. Peptides / analysis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Recombinant Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Androgens / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Drug Resistance, Neoplasm. Enzyme-Linked Immunosorbent Assay. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prostate-Specific Antigen / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12858359.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Gastrointestinal Hormones; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down






Advertisement